title: Complement activation by polyclonal immunoglobulin G1 and G2 antibodies against Staphylococcus aureus, Haemophilus influenzae type b, and tetanus toxoid.
abstract: To obtain information on effector functions of human immunoglobulin G2 (IgG2), we have measured the complement-activating properties of polyclonal IgG subclass antibodies against bacterial antigens. IgG1 and IgG2 were purified from serum samples from five healthy individuals, and complement activation was measured with different bacterial antigens. We used Staphylococcus aureus Wood 46 (STAW), which is a common antigen, Haemophilus influenzae type b (Hib), which is a common pathogenic microorganism in children, and formaldehyde-inactivated tetanus toxin (TT). Bacteria were incubated with antibodies and then incubated with sera from agammaglobulinemic patients as a complement source, and C3c deposition was measured by enzyme-linked immunosorbent assay. We found that anti-STAW IgG2 activated complement to a level similar to that of anti-STAW IgG1. Anti-Hib IgG1 complement activation was as much as seven times higher than that of anti-Hib IgG2 in four individuals. In one individual, anti-Hib IgG2 was more effective in complement activation than anti-Hib IgG1. Anti-TT antibodies showed patterns similar to those of anti-Hib. Our results indicate that IgG2 antibodies may contribute significantly to antibacterial defense. Also, individual differences in antibody effector functions should be taken into account when evaluating the immune status of patients and during early phase 1 studies of new vaccines.
authors.affiliation: Clinical Immunology Laboratory, Academic Medical Center, Amsterdam, The Netherlands.
authors.forename: R G
authors.initials: RG
authors.lastname: Bredius
authors.forename: P C
authors.initials: PC
authors.lastname: Driedijk
authors.forename: M F
authors.initials: MF
authors.lastname: Schouten
authors.forename: R S
authors.initials: RS
authors.lastname: Weening
authors.forename: T A
authors.initials: TA
authors.lastname: Out
mesh_terms: D000907:Antibodies, Bacterial / Q000276:immunology*; D003167:Complement Activation; D015938:Complement Membrane Attack Complex; D003165:Complement System Proteins / Q000378:metabolism; D006023:Glycoproteins / Q000378:metabolism; D006193:Haemophilus influenzae / Q000276:immunology*; D006801:Humans; D007126:Immunoglobulin Allotypes / Q000276:immunology; D007074:Immunoglobulin G / Q000276:immunology*; D066298:In Vitro Techniques; D013211:Staphylococcus aureus / Q000276:immunology*; D013745:Tetanus Toxoid / Q000276:immunology*
chemical_list: D000907:Antibodies, Bacterial; D015938:Complement Membrane Attack Complex; D006023:Glycoproteins; D007126:Immunoglobulin Allotypes; D007074:Immunoglobulin G; C047610:SC5b-9 protein complex; D013745:Tetanus Toxoid; D003165:Complement System Proteins